Critical Contrast: CTI BioPharma Corp. (CTIC) versus GenVec (GNVC)

CTI BioPharma Corp. (NASDAQ: CTIC) and GenVec (NASDAQ:GNVC) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Volatility and Risk

CTI BioPharma Corp. has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, GenVec has a beta of 3.34, suggesting that its share price is 234% more volatile than the S&P 500.

Institutional & Insider Ownership

42.9% of CTI BioPharma Corp. shares are owned by institutional investors. Comparatively, 6.2% of GenVec shares are owned by institutional investors. 8.1% of CTI BioPharma Corp. shares are owned by insiders. Comparatively, 8.1% of GenVec shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CTI BioPharma Corp. and GenVec, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CTI BioPharma Corp. 0 0 1 0 3.00
GenVec 0 2 0 0 2.00

CTI BioPharma Corp. currently has a consensus target price of $7.50, indicating a potential upside of 140.38%. GenVec has a consensus target price of $7.00, indicating a potential downside of 2.68%. Given CTI BioPharma Corp.’s stronger consensus rating and higher probable upside, analysts clearly believe CTI BioPharma Corp. is more favorable than GenVec.

Valuation and Earnings

This table compares CTI BioPharma Corp. and GenVec’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
CTI BioPharma Corp. $36.55 million 2.71 -$50.38 million ($1.91) -1.63
GenVec N/A N/A N/A ($3.65) -1.97

GenVec has higher revenue, but lower earnings than CTI BioPharma Corp.. GenVec is trading at a lower price-to-earnings ratio than CTI BioPharma Corp., indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CTI BioPharma Corp. and GenVec’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CTI BioPharma Corp. -136.76% -418.99% -73.69%
GenVec -3,748.25% -648.22% -271.77%

Summary

CTI BioPharma Corp. beats GenVec on 9 of the 11 factors compared between the two stocks.

CTI BioPharma Corp. Company Profile

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

GenVec Company Profile

GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company’s lead product candidate is CGF166. The Company’s vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.

What are top analysts saying about CTI BioPharma Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CTI BioPharma Corp. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit